Managed Care Approaches to Improve Outcomes in Frontline Therapy for Renal Cell Carcinoma

Program Description

Multiple different subtypes of renal cell carcinoma (RCC) exist, with metastatic RCC (mRCC) comprising 75% to 85% of cases. In patients with advanced disease, overall survival remains low despite the approval of several targeted oral agents and immunotherapies. These novel agents have also become a leading driver of cost in the treatment and management of mRCC. Managed care professionals and pharmacists must navigate the emergence of immunotherapies and the financial challenges that arise when used in combination with oral agents. Patient-specific factors that influence clinical decision making must be carefully considered. This article introduces management tools for pharmacologic therapy in mRCC as well as real-world evidence supporting the use of value-based frameworks to guide formulary management and resource utilization. Safety and efficacy data for guideline-recommended and emerging oral targeted therapy combination approaches are also presented.

Target audience: Managed care pharmacists

Type of activity: Application
Release date: May 31, 2023
Expiration date: February 9, 2025

Time to complete activity: 2.0 hours

Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the most recent clinical guidelines for currently approved therapies and how to integrate emerging regimens into the metastatic renal cell carcinoma (mRCC) treatment paradigm.
• Identify the economic factors and associated cost-effectiveness of oral targeted therapies as part of combination regimens for managing mRCC.
• Apply real-world evidence as a strategy to address health disparities, improve patient management, and optimally utilize resources in the treatment of mRCC.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-23-212-H01-P. The activity is available for CE credit through February 9, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Timothy Y. Mok, PharmD, BCOP, BCPS, has the following financial relationships with commercial interests to disclose:
Consultant: Seagen, Sanofi

The following contributors have no relevant financial relationships with commercial interests to disclose:

Medical Writer

Brigitta U. Mueller, MD, MHCM

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA, CHCP; Evelina Kolychev, PharmD, BCOP; Angelica Archibald; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms